Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 11.25 0.00 08:00:00
Bid Price Offer Price High Price Low Price Open Price
11.00 11.50 11.25 11.25 11.25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 73.72 4.29 0.55 20.5 72
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 0.00 GBX

Allergy Therapeutics (AGY) Latest News

More Allergy Therapeutics News
Allergy Therapeutics Takeover Rumours

Allergy Therapeutics (AGY) Discussions and Chat

Allergy Therapeutics Forums and Chat

Date Time Title Posts
16/1/202017:20Allergy Therapeutics - AGY -3,753
14/7/201620:04Mike Mitchell Panmure Gordon who covers Allergy Therapeutics PLC (LON:AGY)1
16/12/201510:24Allergy Therapeutics-Transforming Allergy Treatment26
03/2/201213:58Ready to ROCKET?-
04/12/200512:00AGY - Allergy Therapeutics79

Add a New Thread

Allergy Therapeutics (AGY) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Allergy Therapeutics trades in real-time

Allergy Therapeutics (AGY) Top Chat Posts

Allergy Therapeutics Daily Update: Allergy Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AGY. The last closing price for Allergy Therapeutics was 11.25p.
Allergy Therapeutics Plc has a 4 week average price of 10.10p and a 12 week average price of 9.90p.
The 1 year high share price is 16p while the 1 year low share price is currently 7.35p.
There are currently 644,117,768 shares in issue and the average daily traded volume is 121,403 shares. The market capitalisation of Allergy Therapeutics Plc is £72,463,248.90.
jpuff: Equally bemused by this depressed share price, but holding tight myself as I'm sure we'll get going up again soon.
eltorres70: How can anyone still believe in this company when all they do is fail and put smoke in people’s eyes, they’ve been doing this for the past 10 years and that’s a fact. And the regression of their share price is hard proof. Finncap is the same source that was suggesting 40p before people lost loads of money. Birch trial proved ineffectiveness of all their current injectible treatments. They have no viable plans for the future, competitors are already light years ahead. Only a naive speculator can still believe the tales they’re telling.
beccasan: I find it hard to firmly believe in AGY as much as you do Jimmy. After all the discussions on this board over the last few months, I am just not that confident anymore. We shall see how the birch trials turn out, but at the moment the market seems to be weak and this company is looking particularly weak against competitors, as it looks like all AGY projects are quite outdated while other similar companies are moving at a faster pace. We shall see once they start putting out news with results, but I currently wouldn't get my hopes too high up, and given the present share price I assume big investors are just as sceptic.
beccasan: I used to think like you but now I am not that sure anymore. This looks like a solid downwards trend, as share price is dropping at last 5% every day! In case bad news awaits in 2019 for the trials, things can get real bad real quick, I am personally very worried, very risky moment
mobox1: Current AGY website states these companies having major holdings: CFR International SPA & Associated Holding 240,584,571 37.82% Southern Fox Investments 127,238,783 22.69% Odey Assest Management 43,747,523 6.88% Black Rock Investment Management 30,368,413 4.79% Invesco 28,618,373 4.50& Black Rock still have someway to go if current % accurate & they want to offload everything. Annoying that they are selling at a time of little news and poor liquidity which knackers the share price. Can't have made them much profit.
gersemi: Today - IC Tip Update: Buy at 27p Megan Boxall The long await phase two clinical trial into Allergy Therapeutics’ (AGY) novel grass allergy vaccine has been successful. The trial managed to discover the appropriate dosage of the drug after a similar trial in 2015 failed to achieve any clinical significance. This latest update means Allergy can progress to its phase three study safe in the knowledge that patients are being given the appropriate dose. If the rest of Allergy’s product development goes according to plan, 2018 should be the last year that losses keep widening, according to Panmure Gordon. The grass vaccine, in particular, could be an enormous commercial success if it manages to pass its final trial thanks to the size of the allergy market, which is largely devoid of long-term treatments. IC View Even with the 9 per cent one-day share price hike which followed these results, Allergy’s share price is still down in the last 12 months. We don’t think that’s a fair reflection of the clinical progress that has been made in that time. Buy at 27p. Last IC View: Buy, 26p, 7 Mar 2018
jpuff: Why the collapse in the share price?
gersemi: Tipped in the IC Tip Update: Buy at 32.3p Tip style - GROWTH Risk rating -HIGH Timescale - LONG TERM Our previous tip -We said BUY at 19.8p on 21 Jul 2016 Tip performance to date - +63% By Megan Boxall The US allergy pharmaceuticals market has the potential to be very lucrative. Roughly 18m Americans sniff and itch their way through the hay fever season each year and, at present, treatment options are limited. But it is also a notoriously tricky sector to navigate. Allergy Therapeutics (AGY) is proof of that, gaining the go-ahead for the phase II clinical trial of its new grass allergy medicine – Pollinex Quattro (PQ) – after 10 years. In 2007, Allergy’s final trial into the efficacy of PQ was put on hold after a participant reported numbness and weakening, which regulators couldn’t be sure had nothing to do with the treatment. That hold was only lifted in 2011, and since then the group has failed to show US regulators an acceptable dosage of the drug. But with demand for PQ so strong, Allergy has been given the go-ahead to try again. The newest dosing study will begin imminently, according to management, and is expected to release results by the second half of 2018. If approved, PQ will be the first injectable allergy treatment available in the US. But as well as sidestepping tight regulation, Allergy Therapeutics must hurdle another demon of the allergy drugs market: the placebo effect. In 1999 a food allergy vaccine made by Peptide Therapeutics successfully helped 75 per cent of patients on a clinical trial tolerate more of the food they were allergic to. Unfortunately, a similar number of patients on the placebo treatment responded the same way, meaning the trial was deemed a failure. It was a similar story at Circassia (CIR) last year when its cat allergy treatment failed to show any significant benefits above the placebo drug, which had improved symptoms by 59 per cent. Many academic studies have found this high placebo effect to be common in allergy drugs trials, but no-one can fully explain why. Allergy Therapeutics should be more immune to placebo effect than its peers. PQ has already successfully improved the symptoms of more than 250,000 patients and is marketed in seven countries. Moreover, the trial has not been designed using the self-report measures that have caused problems for many allergy studies; instead patients’ eyes will be observed for signs of improvement before and after treatment. IC View Investors have been slow to forgive Allergy Therapeutics for its US misfortunes. The share price has gained good momentum in the past few months, but at 32p it is still far from its 2006 highs. There are factors to be wary of that are outside of the company’s control, such as tight US allergy regulation, but demand for PQ is clearly high. If Allergy can crack the tough US regulatory environment, the financial rewards could be big. Buy. Last IC View: Buy, 25p, 03 Apr 2017 -
audigger: An encouraging start to the New Year..... Allergy Therapeutics plc 92.8% Potential Upside Indicated by finnCap Allergy Therapeutics plc with EPIC/TICKER LON:AGY had its stock rating noted as ‘Initiates/Starts’ with the recommendation being set at ‘BUY’ this morning by analysts at finnCap. Allergy Therapeutics plc are listed in the Health Care sector within AIM. finnCap have set their target price at 40 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 92.8% from the opening price of 20.75 GBX. Over the last 30 and 90 trading days the company share price has increased 0.67 points and increased 0.57 points respectively. Allergy Therapeutics plc LON:AGY has a 50 day moving average of 21.27 GBX and the 200 Day Moving Average price is recorded at GBX. The 1 year high share price is 30 GBX while the year low stock price is currently 17.25 GBX. There are currently 598,491,373 shares in issue with the average daily volume traded being 86,871. Market capitalisation for LON:AGY is £122,989,973 GBP.
jimmyloser: From elsewhere on the web Allergy Therapeutics plc 198.6% Potential Upside Indicated by Panmure Gordon by: Amilia Stone 26th September 2016 Allergy Therapeutics plc using EPIC/TICKER code LON:AGY has had its stock rating noted as ‘Retains’; with the recommendation being set at ‘BUY’ this morning by analysts at Panmure Gordon. Allergy Therapeutics plc are listed in the Health Care sector within AIM. Panmure Gordon have set their target price at 53 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 198.6% from today’s opening price of 17.75 GBX. Over the last 30 and 90 trading days the company share price has decreased 1.35 points and decreased 1.3 points respectively. Allergy Therapeutics plc LON:AGY has a 50 day moving average of 19.03 GBX and a 200 day moving average of GBX. The 1 year high for the stock price is 34.82 GBX while the 52 week low for the stock is 17.29 GBX. There are currently 601,432,778 shares in issue with the average daily volume traded being 252,540. Market capitalisation for LON:AGY is £106,934,752 GBP. Allergy Therapeutics plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy. The Company’s business segments are Central Europe, Southern Europe, the United Kingdom and Rest of World.
Allergy Therapeutics share price data is direct from the London Stock Exchange
Your Recent History
Allergy Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200127 08:41:49